Matteo Colombo/DigitalVision via Getty Images Topline Summary and Update Arcus Biosciences, Inc. (NYSE:RCUS) is a cancer-focused biotech I've covered a few times with relative optimism, and as an investment thesis, it has yet to pay off. However, with an important trial update at this year's ASCO Annual Meeting and a number of important upcoming catalysts, I'm inclined to remain upbeat about the company's outlook, despite the more recent setbacks faced by the TIGIT story. Let's take another look. Pipeline U ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Pia Eaves – Vice President-Investor Relations and Strategy Terry Rosen – Chief Executive Officer Jennifer Jarrett – Chief Operating Officer Bob Goeltz – Chief Financial Officer Dimitry Nuyten – Chief Medical Officer Conference Call Participants Yigal Nochomovitz – Citi Jonathan Miller – Evercore Daina Graybosch – Leerink Partners Asthika Goonewardene – Truist Securities Operator Good afternoon ...

COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. CORPORATE PRESENTATION August 8, 2024 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the ...

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.04 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.97 per share when it actually produced a loss of $0.05, delivering a surprise of 94.85%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Arcus Biosciences, which belon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ | --- | --- | |-------------------------------------- ...

Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update • Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 • PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025 • Patient enrollment has completed for the Phase 3 study ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Given the way analysts feel about Arcus Biosciences right now, this h ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - CEO Jennifer Jarrett - COO Bob Goeltz - CFO Dimitry Nuyten - CMO Juan Jaen - President Conference Call Participants Kaveri Pohlman - BTIG Peter Lawson - Barclays Ashiq Mubarack - Citi Jonathan Miller - Evercore ISI Jason Zemansky - Bank of America Jeff La Rosa - Leerink Partners Rosemary Li - Cantor Fitzgerald Operator Hell ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 __________________ ...

Exhibit 99.1 Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update HAYWARD, Calif. – (BUSINESS WIRE) – May 8, 2024 – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules – targeting TI ...